Christer Nordstedt
Chairman bij WNTRESEARCH AB
Profiel
Christer Nordstedt is currently the Chief Executive Officer at Oblique Therapeutics AB, Chairman at Wntresearch AB, and Director at IRLAB Therapeutics AB.
He previously served as the Chief Executive Officer at Vivesto AB in 2022, Senior Vice President-Research & Development at Orion Oyj from 2017 to 2020, and Global Research Manager at Teva GmbH.
Nordstedt holds a doctorate degree from Karolinska Institutet, conferred in 1991.
Actieve functies van Christer Nordstedt
| Bedrijven | Functie | Begin |
|---|---|---|
| WNTRESEARCH AB | Chairman | 01-01-2022 |
| IRLAB THERAPEUTICS AB | Director/Board Member | 01-01-2023 |
| Orion Diagnostica AB | Director/Board Member | - |
| Fermion Ltd. | Director/Board Member | - |
| Snevringe AB | Chairman | - |
Oblique Therapeutics AB
 Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | Chief Executive Officer | 01-12-2022 |
Eerdere bekende functies van Christer Nordstedt
| Bedrijven | Functie | Einde |
|---|---|---|
| VIVESTO AB | Chief Executive Officer | 30-11-2022 |
| ORION OYJ | Chief Tech/Sci/R&D Officer | 05-03-2020 |
Teva GmbH
 Teva GmbH Medical DistributorsDistribution Services Part of Teva Pharmaceutical Industries Ltd., Teva GmbH is a German company that aims to provide high-quality medicines to improve the quality of life of patients. The private company is based in Ulm, Germany. The CEOs are Thomas Andreas Schlenker, Andreas Burkhardt, Christoph Stoller. The company was founded in 2011. | Corporate Officer/Principal | - |
Opleiding van Christer Nordstedt
| Karolinska Institutet | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| ORION OYJ | Health Technology |
| VIVESTO AB | Health Technology |
| WNTRESEARCH AB | Health Technology |
| IRLAB THERAPEUTICS AB | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Teva GmbH
Teva GmbH Medical DistributorsDistribution Services Part of Teva Pharmaceutical Industries Ltd., Teva GmbH is a German company that aims to provide high-quality medicines to improve the quality of life of patients. The private company is based in Ulm, Germany. The CEOs are Thomas Andreas Schlenker, Andreas Burkhardt, Christoph Stoller. The company was founded in 2011. | Distribution Services |
| Orion Diagnostica AB | |
| Fermion Ltd. | |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | Health Technology |
| Snevringe AB |
